Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells. 2009

Naoko Imai, and Hiroaki Ikeda, and Isao Tawara, and Hiroshi Shiku
Department of Immuno-Gene Therapy, Mie University Graduate School of Medicine, Tsu, Japan.

It is becoming increasingly evident that the multifunctionality of effector cells at the single-cell level is an important factor to predict the quality of T-cell response in immunological protection. The significance of the multifunctionality of T cells in anti-tumor immunity, however, remains unclear. Here, we assessed the IFN-gamma and TNF-alpha production and CD107a mobilization in adoptively transferred tumor-antigen-specific CD8(+) T cells at the single-cell level. Tumor growth of the murine fibrosarcoma CMS5 was found to limit the induction of multifunctionality in the transferred cells. These cells exhibited insufficient acquisition of the CD25(high)GITR(high)CD62L(low) phenotype and reduced infiltration in tumor. Depletion of Treg facilitated the induction of high multifunctionality of the transferred cells even in the hosts with progressing tumor, leading to enhanced tumor regression. The multifunctionality of the transferred cells correlated with in vivo CTL activity, and T cells with high multifunctionality harvested from hosts with successful therapy induced tumor regression when re-transferred into the tumor-bearing hosts. These data suggest that the appearance of multifunctional CD8(+) effector T cells in vivo is a critical determinant of the success of anti-tumor immunotherapy and Treg play an important role in the mechanism inhibiting the induction of multifunctionality in effector cells.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D005260 Female Females
D005354 Fibrosarcoma A sarcoma derived from deep fibrous tissue, characterized by bundles of immature proliferating fibroblasts with variable collagen formation, which tends to invade locally and metastasize by the bloodstream. (Stedman, 25th ed) Fibrosarcomas
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D050378 T-Lymphocytes, Regulatory CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells. Regulatory T Cell,Regulatory T-Cell,Regulatory T-Lymphocyte,Regulatory T-Lymphocytes,Suppressor T-Lymphocytes, Naturally-Occurring,T-Cells, Regulatory,Th3 Cells,Tr1 Cell,Treg Cell,Regulatory T-Cells,Suppressor T-Cells, Naturally-Occurring,Tr1 Cells,Treg Cells,Cell, Regulatory T,Cell, Th3,Cell, Tr1,Cell, Treg,Cells, Regulatory T,Cells, Th3,Cells, Tr1,Cells, Treg,Naturally-Occurring Suppressor T-Cell,Naturally-Occurring Suppressor T-Cells,Naturally-Occurring Suppressor T-Lymphocyte,Naturally-Occurring Suppressor T-Lymphocytes,Regulatory T Cells,Regulatory T Lymphocyte,Regulatory T Lymphocytes,Suppressor T Cells, Naturally Occurring,Suppressor T Lymphocytes, Naturally Occurring,Suppressor T-Cell, Naturally-Occurring,Suppressor T-Lymphocyte, Naturally-Occurring,T Cell, Regulatory,T Cells, Regulatory,T Lymphocytes, Regulatory,T-Cell, Naturally-Occurring Suppressor,T-Cells, Naturally-Occurring Suppressor,T-Lymphocyte, Regulatory,Th3 Cell
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Naoko Imai, and Hiroaki Ikeda, and Isao Tawara, and Hiroshi Shiku
January 2022, Journal for immunotherapy of cancer,
Naoko Imai, and Hiroaki Ikeda, and Isao Tawara, and Hiroshi Shiku
June 2005, The Journal of clinical investigation,
Naoko Imai, and Hiroaki Ikeda, and Isao Tawara, and Hiroshi Shiku
August 2007, The Journal of clinical investigation,
Naoko Imai, and Hiroaki Ikeda, and Isao Tawara, and Hiroshi Shiku
December 2004, Journal of immunology (Baltimore, Md. : 1950),
Naoko Imai, and Hiroaki Ikeda, and Isao Tawara, and Hiroshi Shiku
September 2008, Journal of immunology (Baltimore, Md. : 1950),
Naoko Imai, and Hiroaki Ikeda, and Isao Tawara, and Hiroshi Shiku
October 2005, The Journal of experimental medicine,
Naoko Imai, and Hiroaki Ikeda, and Isao Tawara, and Hiroshi Shiku
January 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
Naoko Imai, and Hiroaki Ikeda, and Isao Tawara, and Hiroshi Shiku
November 2004, Cancer research,
Naoko Imai, and Hiroaki Ikeda, and Isao Tawara, and Hiroshi Shiku
March 2023, STAR protocols,
Naoko Imai, and Hiroaki Ikeda, and Isao Tawara, and Hiroshi Shiku
January 2010, Journal of immunotherapy (Hagerstown, Md. : 1997),
Copied contents to your clipboard!